
Glenmark Launches Generic Inlyta Tablets for Kidney Cancer Treatment in US
What Happened?
Glenmark Pharmaceuticals has launched Axitinib Tablets, a generic version of Pfizer's Inlyta, in 1 mg and 5 mg strengths for treating advanced kidney cancer in the US.
Key points
- Glenmark's Axitinib tablets are available in 1 mg and 5 mg strengths.
- The tablets are used to treat advanced renal cell carcinoma (RCC).
- Annual sales of Inlyta in the US were approximately $538.4 million as of September 2026.
- Marc Kikuchi, President of Glenmark North America, emphasized the commitment to affordable medicines.
Key insights
- This launch may enhance Glenmark's market presence in the oncology sector.
- The introduction of generic Axitinib could lead to lower treatment costs for patients.
- Glenmark's focus on affordable medicines aligns with increasing healthcare demands.
Why it matters
The launch could improve access to effective kidney cancer treatment options in the US.
Tags
Entities
Source
Business Standard
